Log in
NASDAQ:OPGN

OpGen Stock Forecast, Price & News

$1.96
-0.01 (-0.51 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.95
Now: $1.96
$1.99
50-Day Range
$1.94
MA: $2.14
$2.47
52-Week Range
$1.02
Now: $1.96
$5.76
Volume344,112 shs
Average Volume3.08 million shs
Market Capitalization$44.08 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.55
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The firms products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
OpGen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPGN
CUSIPN/A
Phone(301) 869-9683
Employees38

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.50 million
Book Value$0.77 per share

Profitability

Net Income$-12,450,000.00
Net Margins-532.22%

Miscellaneous

Market Cap$44.08 million
Next Earnings Date3/23/2021 (Estimated)
OptionableNot Optionable
$1.96
-0.01 (-0.51 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OpGen (NASDAQ:OPGN) Frequently Asked Questions

How has OpGen's stock been impacted by Coronavirus (COVID-19)?

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have decreased by 5.3% and is now trading at $1.96.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of OpGen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OpGen
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OpGen?

Wall Street analysts have given OpGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OpGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OpGen's next earnings date?

OpGen is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for OpGen
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) released its earnings results on Wednesday, November, 11th. The medical research company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04. OpGen had a negative return on equity of 181.57% and a negative net margin of 532.22%.
View OpGen's earnings history
.

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen updated its third quarter 2020 Pre-Market earnings guidance on Thursday, October, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1-1 million, compared to the consensus revenue estimate of $1.6 million.

What price target have analysts set for OPGN?

2 brokers have issued 1-year price targets for OpGen's stock. Their forecasts range from $5.65 to $5.65. On average, they anticipate OpGen's share price to reach $5.65 in the next twelve months. This suggests a possible upside of 188.3% from the stock's current price.
View analysts' price targets for OpGen
.

Are investors shorting OpGen?

OpGen saw a decrease in short interest during the month of October. As of October 30th, there was short interest totaling 1,730,000 shares, a decrease of 18.8% from the October 15th total of 2,130,000 shares. Based on an average daily volume of 2,710,000 shares, the days-to-cover ratio is presently 0.6 days.
View OpGen's Short Interest
.

Who are some of OpGen's key competitors?

What other stocks do shareholders of OpGen own?

Who are OpGen's key executives?

OpGen's management team includes the following people:
  • Oliver Schacht, Chief Executive Officer & Director
  • Johannes Bacher, Chief Operating Officer
  • Timothy C. Dec, CFO, Secretary & Chief Accounting Officer
  • Vadim Sapiro, Chief Information Officer
  • G. Terrance Walker, Senior Vice President-Research & Development

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Who are OpGen's major shareholders?

OpGen's stock is owned by many different retail and institutional investors. Top institutional investors include Schonfeld Strategic Advisors LLC (0.27%), Schonfeld Strategic Advisors LLC (0.27%) and Wedbush Securities Inc. (0.08%). Company insiders that own OpGen stock include Evan/ Fa Jones and NV In Liquidation Curetis.
View institutional ownership trends for OpGen
.

Which major investors are selling OpGen stock?

OPGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold OpGen company stock in the last year include Evan/ Fa Jones, and NV In Liquidation Curetis.
View insider buying and selling activity for OpGen
.

Which major investors are buying OpGen stock?

OPGN stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for OpGen
.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.96.

How big of a company is OpGen?

OpGen has a market capitalization of $44.08 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 38 workers across the globe.

What is OpGen's official website?

The official website for OpGen is www.opgen.com.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (301) 869-9683 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.